PARP Inhibitors for Cancer Therapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28388401.
- Also identified by DOI 10.1016/j.cell.2017.03.034.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 > PARP-3), following a similar drug, Olaparib. It disrupts DNA repair and replication pathways (and possibly transcription), leading to selective killing of cancer cells with BRCA1/2 mutations. Rucaparib is approved for recurrent ovarian cancers with germline or somatic mutations in BRCA1/2.
Medical subject headings
- Antineoplastic Agents
- Indoles
- Ovarian Neoplasms
- Poly(ADP-ribose) Polymerase Inhibitors